Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Alimonti

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Clinical Advances in Hematology & Oncology : H&O|November 10, 2023
Overcoming immune evasion in advanced prostate cancerAndrea Alimonti
Swiss Medical Weekly|January 20, 2017
Aging tumour cells to cure cancer: "pro-senescence" therapy for cancerArianna Calcinotto, Andrea Alimonti
Nature Cell Biology|June 28, 2020
In and out from senescenceSara Zumerle, Andrea Alimonti
Cell Research|August 1, 2025
Neutrophil maturation holds the secret to human tumor suppressionBianca Calí, Andrea Alimonti
Trends in Cell Biology|November 14, 2015
Non-Cell-Autonomous Regulation of Cellular Senescence in CancerDiletta Di Mitri, Andrea Alimonti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?Andrea Alimonti, Gianluigi Ferretti, Francesco Cognetti
Oncoimmunology|September 26, 2015
Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumorsDiletta Di Mitri, Alberto Toso, Andrea Alimonti
Cancer Research|January 27, 2011
PTEN level in tumor suppression: how much is too little?Arkaitz Carracedo, Andrea Alimonti, Pier Paolo Pandolfi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer TherapyDiletta Di Mitri, Alberto Toso, Andrea Alimonti
Oncoimmunology|May 8, 2015
Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunityAlberto Toso, Diletta Di Mitri, Andrea Alimonti
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Clinical Advances in Hematology & Oncology : H&O|November 10, 2023
Overcoming immune evasion in advanced prostate cancerAndrea Alimonti
Swiss Medical Weekly|January 20, 2017
Aging tumour cells to cure cancer: "pro-senescence" therapy for cancerArianna Calcinotto, Andrea Alimonti
Nature Cell Biology|June 28, 2020
In and out from senescenceSara Zumerle, Andrea Alimonti
Cell Research|August 1, 2025
Neutrophil maturation holds the secret to human tumor suppressionBianca Calí, Andrea Alimonti
Trends in Cell Biology|November 14, 2015
Non-Cell-Autonomous Regulation of Cellular Senescence in CancerDiletta Di Mitri, Andrea Alimonti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 2005
Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?Andrea Alimonti, Gianluigi Ferretti, Francesco Cognetti
Oncoimmunology|September 26, 2015
Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumorsDiletta Di Mitri, Alberto Toso, Andrea Alimonti
Cancer Research|January 27, 2011
PTEN level in tumor suppression: how much is too little?Arkaitz Carracedo, Andrea Alimonti, Pier Paolo Pandolfi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer TherapyDiletta Di Mitri, Alberto Toso, Andrea Alimonti
Oncoimmunology|May 8, 2015
Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunityAlberto Toso, Diletta Di Mitri, Andrea Alimonti
Pageof 11